Adding Chemotherapy to Peptide Radiation Therapy Doubles Response Rate in Aggressive Neuroendocrine Tumors
Combining PRRT with capecitabine/temozolomide radiosensitization achieved 90% disease control rate and 26-month median PFS in high-Ki67 neuroendocrine tumors, compared to 60% and 12 months with PRRT alone.
Quick Facts
What This Study Found
PRRT + CAP/TEM achieved 90% disease control rate (70% partial response) vs 60% (20% PR) for PRRT alone, with 26 vs 12 months median PFS, in high-Ki67 neuroendocrine tumors.
Key Numbers
20 patients with histologically confirmed gastroenteropancreatic neuroendocrine tumors with higher proliferation rates and somatostatin receptor positivity.
How They Did This
Retrospective cohort study of 20 patients with GEP-NET (Ki67 15-55%), comparing PRRT alone (n=10) to PRRT + capecitabine/temozolomide (n=10) for at least 2 cycles, with RECIST response, PFS, DSS, metabolic tumor volume, and chromogranin A endpoints.
Why This Research Matters
Aggressive neuroendocrine tumors have limited treatment options. This study suggests adding oral chemotherapy to PRRT can dramatically improve outcomes for patients with higher-proliferation tumors without increasing side effects.
The Bigger Picture
PRRT has been a game-changer for indolent NETs, and this combination approach may extend its benefits to the more aggressive tumors where treatment options are most needed — potentially reshaping the treatment landscape for intermediate-grade neuroendocrine cancers.
What This Study Doesn't Tell Us
Small retrospective study (20 patients); not randomized; potential selection bias; short follow-up for some patients; Ki67 15-55% represents a heterogeneous group; single-center experience.
Questions This Raises
- ?Will randomized prospective trials confirm these dramatic benefits?
- ?What is the optimal number of PRRT + CAP/TEM cycles for maximum benefit?
- ?Are there biomarkers that predict which high-Ki67 patients will respond best to this combination?
Trust & Context
- Key Stat:
- 90% vs 60% disease control rate with PRRT+CAP/TEM vs PRRT alone in aggressive NETs
- Evidence Grade:
- Preliminary evidence from a small retrospective comparison. The dramatic effect size is compelling but requires prospective randomized validation.
- Study Age:
- Published in 2024, supporting the growing trend of combining PRRT with radiosensitizing chemotherapy for aggressive NETs.
- Original Title:
- Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
- Published In:
- Clinical nuclear medicine, 49(3), 207-214 (2024)
- Authors:
- Trautwein, Nils Florian, Hinterleitner, Clemens, Kiefer, Lena Sophie, Singer, Stephan, Mattern, Sven, Schwenck, Johannes, Reischl, Gerald, Sipos, Bence, Lauer, Ulrich M, Dittmann, Helmut, Zender, Lars, la Fougère, Christian, Hinterleitner, Martina
- Database ID:
- RPEP-09406
Evidence Hierarchy
Frequently Asked Questions
Why add chemotherapy to peptide radiation therapy for neuroendocrine tumors?
PRRT works well for slow-growing tumors but is less effective for more aggressive ones. Adding capecitabine/temozolomide makes the cancer cells more sensitive to the radiation carried by the peptide, dramatically improving response rates from 60% to 90% without increasing side effects.
Is this combination treatment available now?
Yes, both PRRT and CAP/TEM are individually approved treatments. This combination can be discussed with your oncologist, though the evidence supporting it is still emerging and prospective clinical trials are needed.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09406APA
Trautwein, Nils Florian; Hinterleitner, Clemens; Kiefer, Lena Sophie; Singer, Stephan; Mattern, Sven; Schwenck, Johannes; Reischl, Gerald; Sipos, Bence; Lauer, Ulrich M; Dittmann, Helmut; Zender, Lars; la Fougère, Christian; Hinterleitner, Martina. (2024). Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.. Clinical nuclear medicine, 49(3), 207-214. https://doi.org/10.1097/RLU.0000000000005006
MLA
Trautwein, Nils Florian, et al. "Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.." Clinical nuclear medicine, 2024. https://doi.org/10.1097/RLU.0000000000005006
RethinkPeptides
RethinkPeptides Research Database. "Radiosensitizing Favors Response to Peptide Receptor Radionu..." RPEP-09406. Retrieved from https://rethinkpeptides.com/research/trautwein-2024-radiosensitizing-favors-response-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.